TOP 100 MEDICAL SITES
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Enzo Biochem's Clinical Labs Unit Enters into Co-Marketing Program with MMF Systems, Inc., for Web-Based Medical Records and Practice Management Software (Business Wire) NEW YORK----Enzo Biochem, Inc., announced today that Enzo Clinical Labs, Inc., its reference lab division serving physicians and medical facilities in the New York metropolitan area, has entered into a trial co-marketing services agreement with privately-owned MMF Systems, Inc. , of New York City, involving MMF’S state of the art medical records system. us.rd.yahoo.com |
Room With a View to Patient Care Health-care centers are seeking to prove that a room's layout and accessories can help healing and cut down on mishaps. A room at Princeton's hospital will test the theory. online.wsj.com |
Inspire Pharmaceuticals, Inc. Q2 2010 Earnings Call Transcript Inspire Pharmaceuticals, Inc. (ISPH)Q2 2010 Earnings Call TranscriptAugust 5, 2010 8:00 am ETComplete Story » seekingalpha.com |
Ziopharm Oncology: Place Your Bets Wall Street Teacher submits:Ziopharm Oncology (ZIOP): UpdateRecent price: $3.50Shares Outstanding: Approx. 49 million.Market Capitalization: Approx. $171millionCash (as of 6/30/10): Approx. $73 millionAs summer ends, it is time for an update on Ziopharm Oncology, a NYC based small molecule cancer drug developer. Much has happened to this little company (some good; some bad) over the last year. Before we jump into specifics, let’s do a quick review of the company’s three drug candidates (see website for more complete descriptions.)Complete Story » seekingalpha.com |
Good News Keeps Coming for Amgen With Aranesp Vote EP Vantage submits:Amgen (AMGN) stands tall. A threat that a US expert panel would vote to tighten the use of its red blood cell booster Aranesp has faded away, another in a string of victories the world’s biggest biotech has scored in recent months to preserve its vital franchise in erythropoietin-stimulating agents (ESAs).While there is no doubt that safety concerns have undermined the California company’s stronghold, several regulatory and competitive threats have dissipated in recent months. As such, when an FDA advisory panel voted Monday to largely preserve the Aranesp label for chronic kidney disease (CKD) patients, Amgen investors and executives must have breathed a sigh of relief, as evidenced by a 2% rise in Amgen’s shares.Complete Story » seekingalpha.com |